BioCentury
ARTICLE | Clinical News

Secnidazole: Phase III data

August 22, 2016 7:00 AM UTC

The double-blind, U.S. Phase III Study 301 in 189 patients ages >=12 with infrequent or recurrent bacterial vaginosis showed that a single dose of 2 g oral Solosec met the primary endpoint of improvin...